Immunotherapy of cancer by chimeric antigen receptors (CAR) modified T-cell has a remarkable clinical potential for malignancies. Meaningly, it is a suitable cancer therapy to treat different solid tumors. CAR is a special recombinant protein combination with an antibody targeting structure alongside with signaling domain capacity on order to activate T cells. It is confirmed that the CAR-modified T cells have this ability to terminate and remove B cell malignancies. So, methodologies for investigations the pro risks and also strategies for neutralizing possible off-tumor consequences of are great importance successful protocols and strategies of CAR T-cell therapy can improve the efficacy and safety of this type of cancers. In this review article, we try to classify and illustrate main optimized plans in cancer CAR T-cell therapy.

嵌合抗原受体（CAR）修饰的T细胞对癌症的免疫疗法在恶性肿瘤方面具有显着的临床潜力。意思是，治疗不同的实体瘤是一种合适的癌症疗法。CAR是一种特殊的重组蛋白组合，具有抗体靶向结构以及信号结构域功能，以激活T细胞。证实了CAR修饰的T细胞具有终止和去除B细胞恶性肿瘤的这种能力。因此，CAR T细胞疗法成功的方案和策略可以提高这类癌症的疗效和安全性，因此，用于调查潜在风险的方法学以及中和可能的非肿瘤后果的策略也非常重要。在这篇综述文章中，我们尝试对癌症CAR T细胞疗法中的主要优化计划进行分类和说明。